[go: up one dir, main page]

WO2001081370A3 - Peptides derives d'histone h2a utiles dans la liberation de genes - Google Patents

Peptides derives d'histone h2a utiles dans la liberation de genes Download PDF

Info

Publication number
WO2001081370A3
WO2001081370A3 PCT/EP2001/004621 EP0104621W WO0181370A3 WO 2001081370 A3 WO2001081370 A3 WO 2001081370A3 EP 0104621 W EP0104621 W EP 0104621W WO 0181370 A3 WO0181370 A3 WO 0181370A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene delivery
histone
derived peptides
nucleus
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/004621
Other languages
English (en)
Other versions
WO2001081370A2 (fr
Inventor
Danuta Balicki
Ernest Beutler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Scripps Research Institute
Original Assignee
Novartis Erfindungen Verwaltungs GmbH
Novartis AG
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfindungen Verwaltungs GmbH, Novartis AG, Scripps Research Institute filed Critical Novartis Erfindungen Verwaltungs GmbH
Priority to EP01929598A priority Critical patent/EP1280822A2/fr
Priority to AU2001256319A priority patent/AU2001256319A1/en
Priority to US10/258,637 priority patent/US20040102606A1/en
Publication of WO2001081370A2 publication Critical patent/WO2001081370A2/fr
Publication of WO2001081370A3 publication Critical patent/WO2001081370A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un nouveau système de libération de gènes, dans lequel un peptide facilitant la libération de gènes, généralement dérivé d'histone H2A, est complexé avec un acide nucléique pour une libération efficace et stable dudit acide nucléique dans une cellule, et finalement vers le noyau. Ladite libération de gènes par peptides est basée sur le principe que des charges positives déneutralisées sur l'histone sont liées électrostatiquement par le squelette de phosphate de l'ADN chargé négativement et que les signaux de ciblage nucléaire dans les histones améliorent l'acheminement de l'ADN vers le noyau pour permettre la transcription.
PCT/EP2001/004621 2000-04-24 2001-04-24 Peptides derives d'histone h2a utiles dans la liberation de genes Ceased WO2001081370A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01929598A EP1280822A2 (fr) 2000-04-24 2001-04-24 Peptides derives d'histone h2a utiles dans la liberation de genes
AU2001256319A AU2001256319A1 (en) 2000-04-24 2001-04-24 Histone h2a-derived peptides useful in gene delivery
US10/258,637 US20040102606A1 (en) 2001-04-24 2001-04-24 Histone H2A -derived peptides useful in gene delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19915300P 2000-04-24 2000-04-24
US60/199,153 2000-04-24

Publications (2)

Publication Number Publication Date
WO2001081370A2 WO2001081370A2 (fr) 2001-11-01
WO2001081370A3 true WO2001081370A3 (fr) 2002-06-27

Family

ID=22736440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/004621 Ceased WO2001081370A2 (fr) 2000-04-24 2001-04-24 Peptides derives d'histone h2a utiles dans la liberation de genes

Country Status (3)

Country Link
EP (1) EP1280822A2 (fr)
AU (1) AU2001256319A1 (fr)
WO (1) WO2001081370A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12312386B2 (en) 2018-05-18 2025-05-27 Hoffmann-La Roche Inc. Targeted intracellular delivery of large nucleic acids

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
JP2009507852A (ja) * 2005-09-08 2009-02-26 エムディーアールエヌエー，インコーポレイテッド リボ核酸の細胞への送達用医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014424A1 (fr) * 1994-11-08 1996-05-17 Medical Research Council Methode de transfert d'adn
US5744335A (en) * 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
WO1998040502A1 (fr) * 1997-03-14 1998-09-17 Life Technologies, Inc. Transfections activees par des peptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100314721B1 (ko) * 1998-01-22 2001-11-23 김일웅 생물학적 활성이 있는 신규한 펩타이드

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014424A1 (fr) * 1994-11-08 1996-05-17 Medical Research Council Methode de transfert d'adn
US5744335A (en) * 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
WO1998040502A1 (fr) * 1997-03-14 1998-09-17 Life Technologies, Inc. Transfections activees par des peptides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANAL CHIM ACTA (1991) 249(1) 215-25 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MILLER, CHARLEEN ET AL.: "SYNTHESIS PURIFICATION AND CHARACTERIZATION OF RAT HISTONE H2A (1-53)-NH2", XP002195949, retrieved from STN Database accession no. 115:227660 *
KIM H S ET AL: "CDNA CLONING AND CHARACTERIZATION OF BUFORIN I, AN ANTIMICROBIAL PEPTIDE: A CLEAVAGE PRODUCT OF HISTONE H2A", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 229, 1996, pages 381 - 387, XP000941591, ISSN: 0006-291X *
PARK CHAN BAE ET AL: "Mechanism of action of the antimicrobial peptide buforin II: Buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 244, no. 1, 6 March 1998 (1998-03-06), pages 253 - 257, XP002195948, ISSN: 0006-291X *
See also references of EP1280822A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12312386B2 (en) 2018-05-18 2025-05-27 Hoffmann-La Roche Inc. Targeted intracellular delivery of large nucleic acids

Also Published As

Publication number Publication date
AU2001256319A1 (en) 2001-11-07
WO2001081370A2 (fr) 2001-11-01
EP1280822A2 (fr) 2003-02-05

Similar Documents

Publication Publication Date Title
Braun et al. Multiple states of protein-DNA interaction in the assembly of transcription complexes on Saccharomyces cerevisiae 5S ribosomal RNA genes.
US8603457B2 (en) Nonsense suppression and genetic codon alteration by targeted modification
EP0830459A4 (fr) Systemes d'hybrides doubles inverses
WO1996041606A3 (fr) Compositions pharmaceutiques ameliorees utilisees pour la therapie genique
WO2001064882A3 (fr) Recepteurs couples a une proteine g, numerotees 1983, 52881, 2398, 45449, 50289, et 52872, et utilisations correspondantes
WO2002000730A3 (fr) Molecules pd-l2 : nouveaux ligands de pd-1 et utilisations de ceux-ci
EP1541690A3 (fr) Transfer de mARN à l'aide de composés polycationiques
WO2005003315A3 (fr) Compositions et methodes pour la transfection assistee par peptide
WO2003042362A3 (fr) Pgc-1$g(b), un nouvel homologue du pgc-1 et leurs utilisations
GB9722320D0 (en) Human cell cycle checkpoint proteins
US20200024365A1 (en) mRNA-ENCODED NANOBODY AND APPLICATION THEREOF
WO2002048329A3 (fr) Caspase 3 derivee d'une membrane, compositions contenant cette caspase et procedes d'utilisation associes
WO2000075358A3 (fr) Molecules toll et leurs utilisations
WO2001081370A3 (fr) Peptides derives d'histone h2a utiles dans la liberation de genes
JP2006345867A5 (fr)
WO2001096392A8 (fr) Molecules 22109, constituant un nouveau membre de la famille des thioredoxines humaines et utilisations correspondantes
WO2001088124A3 (fr) Procede et reactif destine a l'inhibition d'erg
WO1998058055A3 (fr) Acides nucleiques antisens diriges contre le virus de l'hepatite b
WO2002006302A3 (fr) Nouvelles molecules humaines de phospholipases c, 16816 et 16839, et utilisations correspondantes
EP0763205A4 (fr) Sequences d'acides nucleiques regulant l'expression de genes specifiques aux poumons
WO2000067697A3 (fr) Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
Thanedar et al. The fate of the initiator tRNAs is sensitive to the critical balance between interacting proteins
WO2002000859A3 (fr) 46508 nouveau membre humain de la famille des peptidyl-arnt hydrolases et ses utilisations
WO2001094390A3 (fr) 52906, 33408, et 12189, nouveaux elements de la famille de canaux de potassium et leurs utilisations
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001929598

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001929598

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10258637

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001929598

Country of ref document: EP